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Abstract:  Malaria causes approximately 2 million deaths each year primarily in 
children.  The clinical manifestations of the disease are the result of invasion and lysis of 
red blood cells by Plasmodium parasites, the deadliest of which is Plasmodium 
falciparum.  In order to accomplish this cycle of invasion, Plasmodium falciparum 
utilizes a number of proteins including EBA-175 of the Ebl family of proteins.  In this 
thesis, I examine the interactions between EBA-175 and its receptor GpA and self-
association of EBA-175 towards understanding the role of this interaction in invasion.  I 
develop protocols for expression and purification of RII-175, F2-175, GpA, and FITC-
RII-175, as well as, protocols for pulldowns of RII-175 by GpA that identify the minimal 
binding domain of GpA.  I also develop and optimize a FACS assay to quantify RII-175 
binding to GpA on RBCs and utilize the assay to asses the ability of 3’-siallylactose and a 
peptide backbone to inhibit binding. I further examine the influence of 3’-siallylactose 
and a peptide backbone on RII-175 self-association.  Lastly, I describe the development 
of monoclonal antibodies against RII-175 that will be used in future studies to further 
characterize interactions between RII-175 and GpA.  These studies define the minimal 
binding domain of GpA that interacts with RII-175 is the region corresponding to amino 
acids 30 to 50.  It was also shown that 3’-siallylactose, which is important for receptor 
binding, is a weak inhibitor of binding while a peptide backbone corresponding to the 
minimal binding domain cannot inhibit binding alone.  Thus, a fully glycosylated region 
of amino acids 30-50 is required.  The self-association studies of the Kd of dimerization 
of RII-175 is ~10uM consistent with dimerization being important for receptor binding.  
In agreement with the inhibition studies, 3’-siallylactose and peptide backbone failed to 
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influence dimerization.  Further understanding of the RII-175/GpA interactions will help 
to define their roles in invasion and can lead to the production of better malaria 
therapeutics.  
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 Chapter 1: Introduction 
Malaria kills approximately 2 million individuals a year and causes illness in 
approximately 200 million annually [1]. The clinical manifestations of malaria are the 
result of the invasion and lysis of red blood cells (RBCs) by Plasmodium parasites [1].  
Of the four species of Plasmodium that cause malaria, Plasmodium falciparum is the 
deadliest [1].  P. falciparum can be found world wide in tropical regions [fig 1].  The 
region most affected by P. falciparum is sub-Saharan Africa [2].  
Plasmodium parasites represent a heavy economic burden for countries where 
malaria is endemic [2].  As such, research has been conducted with the goal of creating 
vaccines and or drug treatments against Plasmodium parasites.  This has become more 
important as strains of parasites become increasingly drug resistant.  A large variety of 
proteins and cellular processes have been identified as potential targets for vaccines and 
drugs.  One such target is Erythrocyte Binding Antigen (EBA-175), which is involved in 
the erythrocyte stage of the parasite life cycle and is the focus of this thesis. 
1.1:  Malaria Life Cycle 
 The Plasmodium parasite has a complicated life cycle that involves two different 
hosts and multiple stages within each host [1-3].  The two hosts for the parasite are 
humans and the anopheles mosquito.  Within the mosquito, the cycle consists of uptake 
of gametocytes during a blood meal followed by the formation of a macrogametocyte [3].  
The gametocyte develops into an ookinete and then a cyst.  The cyst then ruptures 
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releasing sporozoites that travel to the salivary glands of the mosquito and are ultimately 
injected into the human host during the next blood meal [3].   
Once within the human host the parasite undergoes two main stages in its life 
cycle.  These stages are the liver stage followed by the erythrocyte stage [3].  The liver 
stage consists of invasion, replication within, and lysis of multiple types of liver cells.  
The liver stage culminates in the production of merozoites that can go on to infect RBCs 
[1, 3].  The parasite invades, replicates within, and lyses RBCs in the erythrocyte stage.  
It is the continual invasion and lysis of RBCs which causes the clinical symptoms of 
malaria that include fatigue and severe anemia, which can lead to death [1, 3].  This stage 
is targeted by many antimalarials including the chloroquines.  Also included in the 
erythrocyte stage is the formation of gametocytes during replication within RBCs.   
1.2:  Invasion of Red Blood Cells by Parasite 
 Invasion of RBCs in of itself is also a complicated process involving two main 
pathways of invasion and multiple proteins in each pathway.  The overall invasion 
process can be broken down into four main steps [fig 3] [1].  The first step involves low 
affinity interactions between the merozoite and RBC.  Merozoite Surface Protein-1 
(MSP-1) and Apical Membrane Antigen-1 (AMA-1) are both membrane proteins 
expressed on the surface of merozoites during the erythrocytic stage and are involved in 
this stage of invasion. Although MSP-1 is the most abundant surface protein, the receptor 
for MSP-1 and how it mediates attachment have yet to be defined.  AMA-1 has two roles 
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in invasion.  The first is attachment through an unknown receptor to the RBC surface and 
initiation of the second stage [1]. 
   The second stage involves the apical reorientation of the merozoite so that the 
apical end contacts the RBC membrane and high affinity interactions and the formation 
of the tight junction [1].  The apical reorientation is initiated by AMA-1 through an 
unknown mechanism. The proteins responsible for the formation of the tight junction are 
the Erythrocyte Binding Ligand (EBL) and Reticulocyte-binding Homology (RH) 
families of proteins are involved in this stage of invasion and are essential for invasion. 
Both the EBL and RH families of proteins are expressed during the erythrocytic stage.  
The EBA-175, EBA-140 (BAEBL), and EBA-181 (JESEBL) of the EBL family 
represent the sialic acid dependent pathway and are important for binding erythrocytes 
[fig 4]. The RH family of proteins represents both the sialic acid dependent and the sialic 
acid independent pathway of invasion and are important for binding both erythrocytes 
and reticulocytes [1].   
The third step of invasion is the movement of the tight junction over the surface 
of the merozoite and the shedding of the protein coat [1].  The parasite utilizes an 
actin/myosin motor complex to achieve the active invasion of the RBC.  The forth step of 
invasion is the complete invasion of the RBC and the formation of the parasitophorous 
vacuole [1].   
1.3:  EBL Family of Proteins 
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 The EBL family of proteins is involved in the sialic acid dependent pathway of 
RBC invasion.  The EBL family includes EBA-175, EBA-140 (BAEBL), EBA-181 
(JESEBL), and EBL-1 of P. falciparum and Duffy Binding Protein (DBP) of P. vivax [fig 
4] [1, 4, 5].  The receptors for EBA-175, EBA-140, and EBL-1 are GpA, GpC, and GpB 
respectively, while the receptor for EBA-181 is still unknown. The receptor for DBP is 
the Duffy Antigen Receptor for Chemokines [1, 4, 5].  The sialic acid dependence of 
EBA-175, EBA-140, and EBA-181 was discovered by treating RBCs with neuraminidase 
from V. cholerea, which cleaves the α2-3 linked sialic acid from o-linked glycans [4, 6-
10].  Treatment of the RBCs caused the loss of binding by EBA-175, EBA-140, and 
EBA-181 in rosetting assays [4, 6-10].  In these assays, the malarial protein is expressed 
on the surface of adherent mammalian cells in tissue culture and RBCs are flowed over 
the adherent cells. The RBCs form rosettes, large clumps of RBCs, over the top of the 
cells expressing the malaria protein.  A positive result in a rosetting assay is the formation 
of the rosettes overtop of the adherent mammalian cells. 
The EBL family proteins share homology in their receptor binding domains.  The 
receptor binding domains contain one to two Duffy Binding like (DBL) domains and are 
homologous to Duffy binding region of DBP [1, 5].  The DBL domains are primarily 
alpha-helical and include multiple conserved cysteines [5]. DBP contains one DBL 
domain and the others family members contain two DBL domains [fig 4].  The two DBL 
domains of EBA-175 comprise a larger receptor binding domain named Region II (RII) 
spanning amino acids 145 to 761. The two DBL domains within RII-175 F1 and F2 span 
amino acids 153 to 427 and 442 to 748 respectively [5].   
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1.4:  EBA-175 
 EBA-175 was originally discovered by taking merozoite stage parasite 
supernatant and incubating the supernatant with RBCs [11].  These experiments showed 
multiple proteins which bound RBCs including one with a molecular weight of 175kDa.  
This protein was named EBA-175 [11].  It was later determined that EBA-175 was part 
of the EBL family proteins and expressed by many strains of P. falciparum.  Many lab 
and wild strains such as 3D7 and W2mef use EBA-175 as the primary invasion protein 
[9].   
 The receptor for EBA-175 was discovered through rosetting assays [fig 5] [6].  In 
these assays, RBCs were treated with trypsin and chymotrypsin and RII-175 expressing 
cells were only able to bind chymotrypsin treated cells.  GpA and GpB are the main 
chymotrypsin resistant, trypsin sensitive proteins on the surface of RBCs.  To distinguish 
between these two receptors, GpA and GpB negative RBCs were then used in rosetting 
assays and RII-175 was able to bind GpB negative cells but not GpA negative cells [6].  
These experiments established GpA as the receptor for RII-175. 
 EBA-175 has also been suggested as a target for malarial vaccines.  EBA-
175’s potential as a target for vaccine development has been supported by the evidence 
that antibodies against EBA-175 can be found in patient sera of individuals infected with 
P. falciparum [12, 13].  Individuals who have high titers of antibodies against EBA-175 
also have marginal protection against infection by P. falciparum [12, 13].   
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The structure of RII of EBA-175 was recently solved [fig 6] [5].  In the crystal 
structure, RII-175 appears as a dimer.  In the dimer, the F1 of one monomer interacts 
with the F2 of the monomer in a handshake configuration.  The dimer creates two 
channels going through the center of the dimer, and the surface of these channels is 
highly basic. The F2 domain of each monomer make up roughly two-thirds of two 
channels with the other third contributed by the F1 domains.  Mutations in the dimer 
interface showed a loss of RBC binding in rosetting assays and this result supports the 
biological relevance of the dimer model. Cocrystallization with 3’-siallylactose also 
showed six glycan binding sites in the dimer with 4 sites inside the channels and the other 
2 on the receptor facing surface.  The glycan binding sites were found by cocrystallizing 
3’-saillylactose with RII-175 [5].   
1.5:  GpA 
 GpA is the major siallylated protein on the surface of RBCs and with another 
transmembrane protein, Band3, make up over 50% of the proteins on the surface of RBCs 
[15-16].  GpA is a single pass transmembrane protein that can exist as both a homodimer 
and a heterodimer with GpB on the surface of RBCs.  GpA has three extracellular exons 
with a total of 15 O-linked glycans and 1 N-linked glycan on approximately 60 amino 
acids.  The glycans make up approximately 50% of the total molecular weight of 33kDa.  
The O-linked glycans are important for receptor binding by RII-175 [15-16].   
GpA is part of a family of proteins that includes GpB and GpE and shares 
approximately 95% sequence homology with its family members [fig 5] [15-16].  It is 
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thought that GpB and GpE were derived from homologous recombination as is the case 
for the  43+ known variants of GpA that are derived primarily from GpB but also less 
commonly with GpE.  The majority of the variants are located in exon 3 of GpA. 
Homologous recombination can occur because GpB and GpE both contain an exon 3 in 
the nucleotide sequence.  GpA is the only family member that expresses an exon 3 due to 
a splice site mutation in exon 3 of both GpB and GpE.   Exon 3 contains four O-linked 
glycans that are unique to GpA [15-16].  It is plausible that RII-175 may directly contact 
exon 3 of GpA due to the uniqueness of this sequence.  
The rosetting assays and the crystal structure with glycan binding sites suggest 
two possible models of receptor binding by RII-175 [fig 6] [5].  RII-175’s receptor is 
GpA, which exists on the surface of RBCs as both a homodimer and a heterodimer with 
GpB.  One models suggest are that the GpA dimer threads through the channels to form 
the complex with the glycans in the right orientation.  The other model suggests that the 
GpA dimer wraps around the outside of the RII-175 dimer and places the glycans in the 
right orientation [5].   
1.6:  Focus and scope of thesis 
 While it is known that GpA is the receptor for EBA-175, little is known about 
how they interact.  It is not known how EBA-175 differentiates between GpA and GpB, 
which differ by only 32 amino acids.  It has yet to be shown if these 32 amino acids are 
important for the specific binding of GpA by EBA-175.  While a dimer model of EBA-
175 binding to GpA has been proposed, the exact stoichiometry of binding has yet to be 
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defined.  The crystal structure of the EBA-175/GpA complex has also not yet been 
solved.   
My thesis focuses on the identifying the minimal binding domain of GpA for 
EBA-175 along with the characterization of binding and the characterization of EBA-175 
dimerization.  In chapter 2, I describe the development and optimization of expression 
systems and purification of RII-175 and GpA and the mapping of the minimal binding 
domain of GpA.  In chapter 3, I describe the development and optimization of a 
functional assay for RII-175 that forms the basis for addressing the receptor specificity of 
RII-175 and inhibition of receptor binding by components of the receptor described in 
chapter 4.  In chapter 5, I characterize the dimerization of RII-175 using biophysical 
methods.  In chapter 6, I describe the development of monoclonal antibodies against RII-
175.  
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Figure 1:  W.H.O. 2006 incidence map of P. falciparum[2] 
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Figure 2:  Life cycle diagram for Plasmodium parasites [3] 
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a)  
b)  
Figure 3: a) Diagram of a merozoite and its organelles, b) Scheme for invasion of RBCs 
by merozoite [1] 
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Figure 4:  a) Domain structure of EBL family proteins, b) Alignment of EBA-175, EBA-
140, EBA-181, and EBL-1 amino acid sequence [5] 
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a)  
b)  
Figure 5:  a) Exons and glycosylations for GpA, GpB, GpE [15], b) Identification of 
GpA as the receptor for RII-175 [6] 
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d)  
e) 
 
Figure 6:  a) ribbon structure of RII-175 monomer, b) alingment of F1, green, and F2, 
purple, c)  structure of RII-175 monomer, d)  structure of RII-175 dimer with glycan 
binding sites, e) RII-175 dimer and glycan binding site mutants [5] 
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Figure 7: Dimer model of GpA binding [5] 
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Chapter 2:  Expression of RII-175 and GpA and Mapping of the Minimal Binding 
Domain of GpA 
2.1:  Introduction 
 Protein Expression and purification allows for the study of protein/protein 
interactions outside of the context of cells or organisms and reduces the potential 
masking properties of other proteins present in cells.  RII-175 was previously expressed 
in Pichia pastoris and purified by various chromatography methods [5].  The 
recombinant RII-175 was a glycosylation mutant where certain residues were mutated to 
remove potential aberrant glycosylation by P. pastoris.  The mutations were important for 
expression because P. falciparum lacks complex glycosylation of proteins [5]. Because 
expression using the Pichia pastoris system is labor and time intensive especially for the 
study of multiple mutations, an E. coli system was developed.  The E. coli system also 
has the advantage of not requiring the use of glycosylation mutants due to the E. coli 
lacking a glycosylation system and can be readily used to generate multiple mutants 
when needed.   
GpA has also been expressed before using multiple lines of CHO cells [14]. The 
cell lines used were wild type for glycosylation as well as deficient in various stages of 
O-linked and N-linked glycosylation.  GpA with different types and amounts of 
glycosylation was produced by using these cell lines.  Unfortunately, these GpA 
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constructs were expressed on the surface of the CHO cells and large quantities could not 
be produced using this system [14]. 
Recently a group has developed a protocol for expression of proteins in a 
mammalian expression system [17].  This system utilizes HEK293T cells and the 
pHLFchis or pHLSec vectors.  These vectors use a β-chicken actin promoter to drive the 
expression of large amounts of the protein cloned into the various vectors.  Both the 
pHLFchis and pHLSec vector function have signal sequences for the export of the 
expressed protein outside of the cells.  The protein can then be purified from the media 
[17].  Due to the ability of these vectors to produce large quantities of soluble protein, I 
optimized this system for GpA in order to express soluble protein, which is an advantage 
over the CHO cell expression system. This system was also chosen because it allows for 
the complete glycosylation of GpA, which can not be done in bacterial expression 
systems.   
While the receptor has been identified for RII-175 through rosetting assays, the 
portion of the receptor directly bound by RII-175 has yet to be identified.  Previously, 
fragments of GpA were tested for their ability to inhibit RBC binding in rosetting assays 
[6]. These fragments were obtained by enzymatically cleaving GpA obtained from RBCs 
to produce multiple fragments. No individual fragment was able to inhibit RII-175 
binding to RBCs to the same extent as full length GpA [6].  As a result of the enzymatic 
cleavage of Gpa from RBCs, only a limited number of fragments could be obtained and 
tested.  This method limits the regions that can be used and can cause a binding domain 
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to be missed due to cleavage within the domain. This may be why none of the fragments 
produced were able to inhibit RII-175 binding to RBCs.  The cleavage sites for trypsin on 
GpA are found in exon 3, which results in fragments with incomplete exon 3’s [6].  This 
may be important to understanding why the fragments did not inhibit because exon 3 is 
the only portion of sequence unique to GpA. 
In this chapter, I describe protocols that were developed for the production of RII-
175 and GpA.  These protocols form the basis for the production of recombinant protein 
for all subsequent studies.  In this chapter, I also describe the optimization of a protocol 
for pulldowns with full length and the truncations of GpA and the binding of GpA 
truncations by RII-175 to show functionality of the expressed proteins and to identify the 
minimal binding domain. 
2.2:  Materials & Methods 
2.2.1:  Expression of EBA-175.  RII-175 (amino acids 145 to 761) and F2-175 (amino 
acids 442 to 748) were expressed in BL-21 E. coli cells using a pet28 vector.  The cells 
were grown shaking at 37oC to an O.D. 600 of 0.6 and induced with IPTG.  The cells 
were then grown for an additional 3 to 5 hours shaking at 37oC.  The cells were then 
pelleted and resuspended in 10mL/L cells of 50mM Tris pH 8, 100mM NaCl, 5mM DTT, 
0.25mg/mL Lysozyme, and 1 complete protease tablet per 30mL of buffer and frozen at -
80oC.  The cells were later lysed using sonication and the inclusion bodies pelleted.  The 
inclusion bodies were washed 3 times in 50mM Tris pH 8, 100mM NaCl, 5mM DTT, 
0.5% Triton X-100 and once in 50mM Tris pH 8, 100mM NaCl, 5mM DTT.  The protein 
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was then denatured with 6M guanidine hydrochloride, 50mM Tris pH 8, 100mM NaCl, 
5mM DTT overnight at 4oC.  100mg of protein was used per liter of refolding buffer 
(200mM Tris pH 8, 10mM EDTA, 400mM L-arginine, 0.1mM PMSF, 2mM reduced 
glutathione, 0.2mM oxidized glutathione).  The protein was refolded for 48 to 72 hours at 
4oC.  The refolded protein was concentrated using Amicon concentrators to a 
concentration of approximately 15mL per liter of refolding buffer.  The concentrated 
protein was dialyzed overnight at 4oC against 50mM MES pH 6, 200mM NaCl (1L 
dialysis buffer per 1L refolding buffer).  The dialyzed protein was then concentrated to 
5mL/1L refolding buffer.  Each 5mL of protein was then purified by gel filtration 
chromatography using a Hiload 16/60 superdex 200 prepgrade column with 10mM MES 
pH 6, 200mM NaCl and the peak fractions of each run were combined and purified by 
gel filtration chromatography an additional 2 to 3 times.  The peak fractions from the 
final gel filtration purification were than concentrated to a concentration of 15mg/mL.  
2.2.2:  Expression of GpA.  GpA_FL (aa1-60) and GpA truncations [table 1], cloned 
into a pHLFchis vector containing the GpA signal sequence, were transiently transfected 
into 70-90% confluent HEK293T cells using the method described in Aricescu 2006.  
Media was then harvested four days later.  The media was diluted 3 times with His-tag 
buffer A (50mM Tris pH 8, 100mM NaCl, 10mM Imidazole pH 8).  The diluted media 
was then run over a nickel-agarose column and eluted with His-tag buffer B (50mM Tris 
pH 8, 100mM NaCl, 500mM Imidazole pH 8).  To separate out the various glycosylation 
states of the GpA produced, the GpA was purified by anion exchange chromatography 
using a monoQ 5/50 GL column with buffers (A) 25mM Tris pH 8 and (B) 25mM Tris 
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pH 8, 1M NaCl.  A gradient from 0 to 40% of buffer B was used to separate the various 
glycosylation states which eluted at 130mM NaCl and 230mM NaCl. 
2.2.3:  GpA Binding in a Pulldown.  40ug of each GpA construct (full length and 
truncations) was incubated with 1uL 15mg/mL RII-175 and 20uL of ProteinA beads in a 
total of 100uL in 50mM Tris pH 8, 200mM NaCl, 0.1% Triton X-100 for 30min on ice. 
The beads were then washed 3 times.  The beads were then resuspended in 10uL of SDS-
PAGE dye and the samples run on a 10% SDS-PAGE gel. 
2.3:  Results 
2.3.1:  RII-175 Expression and Purification 
 An E. coli system was chosen for the expression of RII-175 and F2-175 because it 
can produce milligram quantities of protein quickly and without the use of glycoslylation 
mutants.  F2-175 was expressed and purified in addition to RII-175 because it has similar 
binding ability to the full regionII.  Both his-tagged and untagged RII-175 and F2-175 
were expressed in E. coli using the pet28 vector.  The denatured protein extracted from 
the E. coli inclusion bodies was refolded in standard refolding buffer as described in 
Materials and Methods.  Multiple methods were tried to purify the refolded protein.  The 
first method of purification was to concentrate 1L of refolded protein which was then 
purified by gel filtration chromatography with Tris buffer pH 8 and 200mM NaCl.  The 
subsequent peak was purified by cation exchange chromatograpy. Unfortunately, this 
method resulted in aggregate protein precipitating on the gel filtration column.  As a 
result, other methods of purification were developed.  
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 The next method used was to concentrate the refolded protein and dialyze the 
protein against 50mM MES pH 6 200mM NaCl.  Dialysis at this step prevented 
precipitation of the protein on the columns. The dialyzed protein was then purified by 
anion exchange chromatography.  The resultant peak was further purified by gel filtration 
chromatography. Unfortunately, this protein still had aggregate in the purified sample.   
The next method of purification was to use the previous method and add two to 
three additional gel filtration chromatography steps to reduce aggregate contamination.  
This resulted in protein with minimal aggregate contamination. While this method 
resulted in pure protein it was time and labor intensive.  
The method was modified in an attempt to reduce the time and labor needed to 
produce the recombinant protein. The method used was to follow the previous method 
but exclude the cation exchange step because the cation exchange step did not increase 
the purity of the protein. This method resulted in similar purification to the previous 
method with one less step.   
The final protocol used was to refold the protein in standard refolding buffer and 
dialyze the refolded protein.  The dialyzed protein was then purified by three to four 
rounds of gel filtration chromatography. A typical GF200 chromatograph and SDS-
PAGE gel of the fractions corresponding to the major peak can be found in figure 8.  A 
typical yield for this protocol is 1-5mg per liter of refolding buffer. 
2.3.2:  GpA Expression and Purification 
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 A mammalian expression system was chosen for GpA because it could be used to 
produce milligram quantities of completely glycosylated protein quickly. The 
extracellular portion of GpA (amino acids 1 to 60) was cloned into the pHLFchis 
construct with the addition of a precision protease site between the GpA sequence and the 
Fc sequence [fig 9].  The GpA construct was transiently transfected into HEK293 cells.  
A time course was done to measure the production of GpA over time [fig 9].  The 
expression of GpA peaked at four days post transfection.  All subsequent transfections 
were harvested four days post transfection.   
GpA was purified from the media using a nickel-agarose column.  The resulting 
eluted protein was then used in subsequent experiments.  The GpA at this point appears 
as a smear on an SDS-PAGE gel that is likely the result of various stages of glycosylation 
in the GpA sample.  The different glycosylation states can be further separated by anion 
exchange chromatography presumably because of the difference in charge represented by 
the negatively charged sialic acid containing glycans [fig 9].   
2.3.3:  Expression and Purification of GpA Truncations: 
 Previously only full length GpA has been expressed and only as a transmembrane 
protein on the surface of CHO cells. Also, the fragments of GpA used in experiments to 
inhibit binding were produced through enzyme treatment of GpA from RBCs. This 
expression system was developed to produce multiple overlapping fragments of GpA and 
mutants quickly.   
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Overlapping truncations of the extracellular portion of GpA were cloned into the 
pHLFchis vector [table 1].  The truncations were transiently transfected into HEK293 
cells and the media harvested four days post transfection.  All truncations expressed 
under these conditions [fig 10].  While truncations 3, 5, and 2-4 expressed well, 
truncation 2 only expressed moderately well and truncations 1 and 4 expressed poorly.  
Never-the-less, all truncations of GpA can be obtained. 
2.3.4:  Optimization of Pulldown Conditions 
 A method to examine protein/protein interactions in the absence of cells has not 
been developed for Gpa and RII-175, therefore, I developed a pulldown assay to examine 
the binding of GpA by RII-175 in a cell free assay.  The first pulldowns used nickel-
agarose beads in conjunction with the his-tag on the GpA [fig 11].  In this pulldown, GpA 
was purified by cation exchange chromatography, which resulted in three distinct peaks 
and each peak was incubated with RII-175.  Peak 2 and Peak 3 of GpA bound RII-175 in 
the pulldown.  Unfortunately, the RII-175 bound non-specifically to the nickel-agarose 
beads.   
 In order to eliminate the non-specific binding of RII-175 to the nickel-agarose 
beads, the imidazole in the wash buffer was increased from 10mM to 100mM.  Peak 2 
and Peak 3 of GpA still bound RII-175 in the pulldown.  Unfortunately, the RII-175 still 
bound non-specifically to the nickel-agarose beads.  
 In order to eliminate any non-specific binding by RII-175, the type of beads used 
was changed to proteinA-agarose beads [fig 11]. ProteinA-agarose beads can be used 
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with the GpA constructs because all GpA contructs are conjugated to the Fc portion of an 
IgG antibody and proteinA binds the Fc portion of antibodies.  The three peaks of GpA 
were again used and peak 2 bound RII-175.  All three peaks showed binding, but the 
higher molecular weight peaks bound RII-175 the most.  Unfortunately, while there was 
less non-specific binding of RII-175 on the proteinA beads, the non-specific binding was 
not completely eliminated. 
In order to eliminate all non-specific binding by RII-175, a detergent was added to 
the wash buffer [fig 11].  The three peaks of GpA were again used and peak 2 bound RII-
175.  Only the higher molecular weight peaks bound RII-175.  In this pulldown, there 
was no non-specific binding of the beads by RII-175.  The final conditions used in the 
pulldown were 50mM Tris pH 8, 50mM NaCl, 0.1% Triton X-100 and proteinA-agarose 
beads. 
2.3.5:  Pulldown with GpA Truncations 
 In order to identify the portion of Gpa bound by RII-175, a pulldown was 
conducted with full length and truncations of GpA.  The first pulldown conducted was 
with the buffer used in the above experiment.  At 50mM NaCl, all the truncations bound 
RII-175.   
 To eliminate any non-specific binding of RII-175 by a salt gradient was used [fig 
12].  The salts used were 50mM NaCl, 100mM NaCl, and 200mM NaCl.  All truncations 
bound RII-175 at 50mM NaCl and 100mM NaCl.  At 200mM NaCl, full length GpA and 
truncation 4 bound RII-175 strongly.  Truncation 2 also weakly bound RII-175.  
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2.4:  Discussion 
 A protocol to purify RII-175 and F2-175 from E. coli was developed and 
optimized. The final yield for this protocol is approximately 1 to 5 mg/ L refolding 
buffer.  A protocol for the production of full length GpA and GpA truncations using 
HEK293 cells was developed and optimized.  The final yield for this protocol is 
approximately 13mg/L harvested media.  The production of purified RII-175 and GpA 
allows for further investigation into the interactions between RII-175 with itself and its 
receptor.   
To show that RII-175 and GpA (full length and truncations) are functional a 
pulldown protocol was developed. In the pulldown, RII-175 binds truncation 4 the 
strongest of all the truncations.  Truncation 4 corresponds to amino acids 30 to 50 of GpA 
and includes all four glycosylations in exon 3.  It is likely that amino acids 30 to 50 of 
GpA are the minimal binding site for RII-175.  RII-175 also binds truncation 2 weakly.  
Truncation 2 contains seven glycosylations and an additional three residues that could 
potentially be glycosylated.  RII-175 may bind truncation 2 weakly because of the large 
number of glycosylations.  The glycosylations are important for binding as evidenced by 
the loss of binding in rosetting assays upon treatment with neuraminidase.  This is also 
seen in the pulldown with the anion exchange purified GpA.  In this pulldown, RII-175 
binds only the high molecular weight peaks which may correspond to a higher level of 
glycosylation. Development of further functional assays for RII-175 are described in the 
next chapter.  
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a)  
 
b) 
  
Figure 8:  a) GF200 column purification of RII-175, b) GF200 column purification of F2-175 
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a)
 
b) d)   
c)  
Figure 9:  Expression of GpA a) diagram of GpA construct, b) Nickel column 
purification of HEK293T cells transfected with either no vector, pHLFchis vector, or 
GpA vector (full length), c) Time course of GpA production by transfected HEK293T 
cells, d) anion exchange purification of GpA 
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Truncation: Sequence: 
1 SSTTGVAMHTSTSSSVTKSY 
2 TSTSSSVTKSYISSQTNDTHK 
3 YISSQTNDTHKRDTYAATPRA 
4 KRDTYAATPRAHEVSEISVRT 
5 AHEVSEISVRTVYPPEEETGE 
2-4 TSTSSSVTKSYISSQTNDTHKRDTYAATPRAHEVSEISVRT 
 
Table 1:  Amino acid sequence of the extracellular portion of GpA in each truncation 
clone and diagram of truncations with glycosylations (red) O-linked, (blue) N-linked 
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Figure 10: Expression of GpA full length and truncations purified by Nickel-agarose 
column 
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a)
 
b) 
c)  
Figure 11:  RII-175 Pull down with GpA purified on MonoQ column a) 10mM Imidazole 
washes on nickel beads, b) proteinA beads, c) proteinA beads with 0.1% trition X-100 washes 
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Figure 12:  GpA pulldown of RII with full length GpA and GpA truncations 
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Chapter 3:  Validation of Protein Binding in a Functional Assay 
3.1:  Introduction 
 Flow Cytometry (FACS) is a method often used to differentiate populations 
within samples of cells [18].  In FACS, a sample is injected into a flow cell and then 
flows past a laser at approximately 1 cell at a time.  The cell scatters light in both the 
forward and side directions and is read by a set of detectors [fig 13].  The forward scatter 
gives the approximate size of the cell that passed by the laser.  The side scatter detects 
organelles like the granules found in neutrophils.  Both types of scatter can be used to 
define different populations in a sample like peripheral blood [18].   
 FACS can also be used to detect fluorescent stains and dyes by adding additional 
lasers and detectors. [fig 13] [18].  Fluorescent dyes that bind DNA can be used to detect 
P. falciparum infected RBCs from uninfected RBCs due to only the parasite having 
DNA.  The uninfected RBCs can be separated from infected RBCs based on the detection 
of fluoresce if the flow cytometer is attached to a cell sorter.  Fluorescent dyes conjugated 
to antibodies can also be used in FACS to detect proteins on the surface of cells or 
proteins in complex with proteins on the surface of cells [18].  Multiple dyes can be used 
at once to differentiate between different populations.  Both the forward and side scatter 
and the fluorescence detection can be combined to easily differentiate population of cells 
in mixed samples [18]. 
 In this chapter, I describe the development of a functional FACS assay for the 
recombinant RII-175 purified as described in chapter 2.  FACS assays can be used to test 
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a multitude of conditions for binding and can be used to obtain the IC50s for inhibitors 
and protein/protein interactions on the surface of cells.   
3.2:  Materials and Methods 
3.2.1:  Initial Binding of RBCs by RII-175.  Red blood cells (RBC) were obtained from 
the Barnes Jewish Children’s Hospital Blood Bank.  500,000 RBCs are diluted in 500uL 
DMEM with 10% FCS.  His tagged 15mg/mL RII-175 was added to a concentration of 
either 66uM or 9uM and the mixture incubated on ice for one hour.  The RBCs were then 
washed three times with DMEM with 10% FCS.  Mouse anti-his antibody from Qiagen 
was added to the RBCs.   Alexafluor 647 conjugated anti-mouse IgG antibody from 
Invitrogen was diluted 1:500 in DMEM with 10% FCS.  100uL of the diluted antibody 
was added to the washed RBC and incubated on ice for one hour.  The RBCs were then 
washed three times.  The RBCs were then resuspended in 100uL DMEM with 10% FCS.  
The RBCs were then analyzed using a fluorescent microscope. 
3.2.2:  Optimization of Enzyme Treatment of RBCs to Prevent Clumping.  RBCs 
were incubated with 1mg/mL chymotrypsin overnight.  The cells were then used as 
described above in RII binding. 
3.2.3:  Optimization of Anticoagulant treatments to Prevent Clumping. EDTA: RII-
175 was incubated with RBCs as described in above in RII binding with the buffer being 
DMEM 10% FCS 7mM EDTA instead of DMEM 10% FCS.  Heparin: RII-175 at 10uM 
and 1uM was incubated with RBCs in DMEM 10% FCS buffer with heparin at 
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concentrations of 60units/mL, 30units/mL, or 12 units/mL.  The mixture was then 
incubated with antibodies as described above in RII binding. 
3.2.4:  Optimization of Salt and Protein Concentration conditions to Prevent 
Clumping.  RII-175-his at 0nM, 40nM, 200nM, 320nM, and 1000nM were each 
incubated with RBCs in DMEM 10% FCS with 150mM NaCl, 200mM NaCl, 250mM 
NaCl, 300mM NaCl, 350mM NaCl, and 400mM NaCl for 1 hour on ice.  The samples 
were then washed three times with DMEM 10% FCS that have their corresponding salt 
concentration.  The samples were then incubated with anti-his antibody conjugated to 
FITC for 1 hour on ice. The samples were then washed three times with DMEM 10% 
FCS that have their corresponding salt concentration.  The RBCs were resuspended in 
2mL DMEM 10% FCS that have their corresponding salt concentration and were then 
analyzed using a BD FACScanto machine available in the Goldberg lab. 
3.2.5:  FITC labeling of RII-175 and FACS. 1.5mg of 15mg/mL RII-175 was diluted in 
1mL PBS pH 6, 50mM EDTA and mixed with 10uL 10mg/mL FITC in DMSO.  The 
mixture was incubated rotating at room temperature for 1hr.  The mixture was then 
diluted in 10mL 25mM MES pH 6, 100mM NaCl.  The diluted protein was then run over 
2mL monoS sepharose resin and the protein eluted with 5mL 25mM MES pH 6, 500mM 
NaCl.  The protein was then concentrated to 1mL and purified by gel filtration 
chromatography using a superdex 200 10/300 GL column.  Incorporation of the FITC 
label was verified using a phosphoimager.  The resultant labeled peak was then 
concentrated to 15mg/mL. 1uM RII-FITC was then added to 500,000 RBCs in 500uL of 
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DMEM 10% FCS 250mM NaCl and incubated for one hour on ice.  The cells were 
washed three times with DMEM 10% FCS 250mM NaCl and resuspended in 2mL 
DMEM 10% FCS 250mM NaCl.  The cells were then imaged using a fluorescent 
microscope and also analyzed using a BD FACScanto machine available in the Goldberg 
lab.  
3.3:  Results 
3.3.1:  Initial Binding of RBCs by RII-175 
 To initially asses the ability of the recombinant RII-175 to bind RBCs, 66uM RII-
175-his purified as described in chapter 2 was added to RBCs and then incubated with a 
mouse anti-his antibody followed by a goat anti-mouse IgG antibody conjugated to Alexa 
647.  The RBCs were then imaged using a fluorescent microscope [fig 14].  Only the 
RBCs incubated with RII-175 were positive for fluorescence.  The RBCs incubated with 
RII-175 also formed large clumps that do not resuspend and were positive for 
fluorescence while negative controls lacking RII-175 did not fluoresce or clump.  This 
was also seen when the RII-175 concentration was decreased to 9uM.  The clumping only 
occurs when RBCs are incubated with RII-175 and is therefore RII-175 dependent.  
F2-175 has a similar binding ability as RII-175 when used in rosetting assays and 
was therefore tested for binding RBCs in solution.  F2-175-his was also incubated with 
RBCs at the same concentrations as previously used for RII-175.  The F2-175 also 
clumped the RBCs and these clumps were positive for fluorescence [fig 15].  The F2-175 
also clumping indicates that it is a property of the recombinant protein binding to RBCs.  
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Unfortunately, clumps are not conducive to FACS assays for two main reasons:  1) small 
clumps that flow through the flow stream will be read as one event instead of multiple 
events and can under represent the true percentage of the population that is positive for 
binding, 2) the capillary through which the cells pass is very small and large clumps will 
clog the system. 
3.3.2:  Optimization of Enzyme Treatment of RBCs to Prevent Clumping 
 The only known function for GpA is to prevent clumping of RBCs.  To test if the 
clumping is due to other proteins interacting when GpA is bound by RII-175, enzyme 
treatment of RBCs was conducted before incubation with RII-175.  Specifically 
chymotrypsin was used because GpA is chymotrypsin resistant and treatment of RBCs 
with chymotrypsin will cleave other proteins while leaving GpA whole.  When these 
treated RBCs were incubated with the lowest concentration of RII-175 previously used, 
the RBCs still clumped and the clumps were positive for fluorescence.  While this 
treatment did not inhibit binding, the treatment did not reduce the clumping. 
3.3.3:  Optimization of Anticoagulant treatments to Prevent Clumping 
 Anticoagulants are compounds used in solutions containing RBCs to prevent 
clumping and clotting of RBCs, therefore, I wanted to examine if anticoagulants could 
prevent the clumping when RII-175 binds RBCs.  Two commonly used anticoagulants 
are EDTA and heparin.  RBCs were incubated with the lowest concentration of RII-175 
previously used in DMEM with EDTA at concentration of 7mM.  The RBCs still 
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clumped and the clumps were positive for fluorescence. Unfortunately, EDTA did not 
decrease clumping significantly on its own.   
 Heparin was also used in an attempt to prevent clumping.  RII-175 at 10uM and 
1uM was incubated with RBCs and heparin at concentrations of 60units/mL, 30units/mL, 
or 12 units/mL.  RBCs incubated with RII-175 alone clumped cells and were positive for 
fluorescence [fig 16].  Unfortunately, all concentrations of heparin prevented clumping of 
RBCs but also prevented RII-175 binding in the 1uM RII-175 samples and greatly 
reduced binding in the 10uM samples shown by the loss of fluorescence.  
3.3.4:  Optimization of Salt and Protein Concentration conditions to Prevent 
Clumping 
 It is possible that salt and the concentration of protein could affect the clumping 
of the RBCs.  The next treatment used to prevent clumping of the RBCs upon RII-175 
binding was a salt gradient combined with a titration of RII-175.  RII-175-his at 0nM, 
40nM, 200nM, 320nM, and 1000nM were each incubated with RBCs in DMEM with 
150mM NaCl, 200mM NaCl, 250mM NaCl, 300mM NaCl, 350mM NaCl, and 400mM 
NaCl [fig 17].  The concentration of RII-175 with the best overall binding was 1000nM 
(1uM).  The other concentrations did not have high enough signal to justify using.  The 
1uM sample bound RBCs up to 250mM NaCl, and the clumping decreased as the salt 
concentration increased [fig 17].  The conditions of 1uM RII-175 and 250mM NaCl were 
used in all subsequent FACS assays. Thus, it appears that the clumping is due to 
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electrostatic interactions and these interactions can be limited by increasing the salt 
concentration in the buffer. 
3.3.5:  RII-FITC labeling and use in FACS   
 To make the FACS assay more efficient and reduce the number of washes, RII-
175 was labeled with FITC.  RII-175 was incubated with either FITC dissolved in DMSO 
or Carbonate buffer.  The lowest concentration of FITC used, 10uL of 10mg/mL DMSO, 
was able to label the RII-175 [fig 17].  The RII-FITC was run over a cation exchange 
resin column to purify the RII-FITC from free FITC.  The subsequent protein was 
purified by gel filtration chromatography.  The labeled protein ran as one peak and the 
FITC label was verified by a phosphoimager [fig 18].  The protein was then concentrated 
to 15mg/mL and used to label RBCs.  The FITC labeled RII-175 was able to bind RBCs 
and was positive for fluorescence [fig 19].  The FITC labeled RII-175 when incubated 
with RBCs was also able to produce a positive signal in a FACS assay [fig 19]. 
3.4:  Discussion 
 Recombinant RII-175 that was expressed and purified is functional for RBCs 
binding, and can now be used to characterize its interactions with GpA and itself.  The 
functional assay developed can be further used to study inhibitors of various kinds, i.e. 
small molecules, receptor fragments, antibodies, etc.  The development of the FITC-RII-
175 decreases the amount of time required for the FACS assay and can be used to test 
inhibitors. One disadvantage to the FITC-RII-175 in a FACS assay is that the label could 
interfere with the ability of antibodies specific to RII-175 to bind by obscuring the 
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epitope for the antibody.  Receptor specificity of the RII-175 will be described in chapter 
4 and utilizes the FACS assay developed in this chapter. 
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a)  
b)  
Figure 13: a) diagram of forward and side scatter in FACS, b) diagram of laser, filters, 
and detectors in FACS [18] 
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Figure 14:  RII-175 binding of RBCs using a secondary antibody conjugated to 
Alexafluor 647 
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Figure 15: RII-175 and F2-175 binding of RBCs using a secondary antibody conjugated 
to Alexafluor 647 
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a)  
b)  
Figure 16: Influence of heparin on RII-175 binding to RBCs, a) percentage of positive cells 
for heparin samples, b) Dot plots of heparin samples in “a” 
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a)  
b) 
 
Figure 17: a) Salt gradient and RII-175 titration in FACS, b) Dot Plots for 1000nM  
RII-175 
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a)  b)  
Figure 18:  RII-175-FITC, a)  FITC titration in Carbonate buffer and DMSO (top) FITC 
fluorescence detected by phosphoimager (bottom) Commassie Brilliant Blue stain of 
same gel, b) Gel filtration purification of RII-175-FITC after cation resin purification(on 
gel) (top) FITC fluorescence detected by phosphoimager (bottom) Commassie Brilliant 
Blue stain of same gel 
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a) Bright Field FITC 
no RII-FITC 
  
RII-FITC 
  
b)                             
Figure 19:  RII-175-FITC binding of RBCs a) RII-175-FITC fluorescence microscopy, b) 
RII-175-FITC FACS 
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Chapter 4:  Receptor Specificity of RII-175 and Inhibition of Binding by Receptor 
Components 
4.1:  Introduction 
 It has previously been shown that RII-175 binds to GpA on the surface of RBCs.  
GpA is the main chymotrypsin resistant, trypsin sensitive receptor on the surface of 
RBCs [6].  Trypsin cleaves GpA at two sites, amino acids 31 and 39, both of which are 
located in exon 3. Rossetting assays have shown that when RBCs are incubated with 
either chymotrypsin or trypsin, RII-175 can only bind the chymotrypsin treated cells [6].  
This establishes a reproducible pattern for receptor specificity in binding assays.   
 Binding Assays have also been used to assess the potency of inhibitors.  It has 
previously been shown that SL can inhibit RII-175 binding RBCs in rosetting assays in 
the low milimolar range [19].  Related compounds have also been analyzed in rosetting 
assays. Of those tested, SL was the best inhibitor [19]. The major drawbacks to using the 
rosetting assay are that you cannot readily quantify expression of the malaria protein 
expressed in tissue culture and its surface expression and it is very hard to accurately 
quantify the number of RBCs bound to the cells expressing the malaria protein. Along 
with the inability to quantify the RBCs forming rosettes, it is also difficult to quantify 
what signifies a rosette (i.e. 5 RBCs or 100 RBCs).  Other binding assays like a FACS 
assay can be used to accurately and quantitatively assess the potency of inhibitors.  
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 In this chapter, I describe the receptor specificity of RII-175 and the use of small 
molecules in an inhibition study using the quantitative FACS assay developed in chapter 
3.   
4.2:  Materials and Methods 
4.2.1:  RII-175 binding to RBCs.  Red blood cells (RBC) were obtained from the Barnes 
Jewish Children’s Hospital Blood Bank.  500,000 RBCs were diluted in 500uL DMEM 
with 10% FCS.  His tagged 15mg/mL RII-175 was diluted 1:10 in DMEM with 10% 
FCS.  25uL of the diluted RII-175 was added to the RBCs (1uM RII final concentration) 
and the mixture incubated on ice for one hour.  The RBCs were then washed three times 
with DMEM with 10% FCS.  FITC conjugated anti-his antibody from Invitrogen was 
diluted 1:500 in DMEM with 10% FCS.  100uL of the diluted antibody was added to the 
washed RBC and incubated on ice for one hour.  The RBCs were then washed three 
times.  The RBCs were then resuspended in 2mL DMEM with 10% FCS.  The RBCs 
were then analyzed using a BD FACScanto machine.  All conditions were conducted in 
triplicate. 
4.2.2:  Treatment of RBCs. RBCs were incubated with either 2mg/mL Trypsin, 1mg/mL 
Chymotrysin, or 20uL of anti-GpA antibody from Santa Cruz Biosystems overnight at 
4oC.  The treated RBCs were then used in binding assays as described above. 
4.2.3:  IC50 curves. His tagged 15mg/mL was diluted 1:10 in DMEM with 10% FCS.  
Compound (siallylactose (sl), peptide (pep), or siallylactose & peptide(slp)) was added to 
25uL of diluted RII-175 to reach the desired concentration in a total of 50uL and the 
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mixture incubated at 4oC overnight.  The mixture was then added to RBCs prepared as 
described above in RII binding and the FACS assay conducted as described above in RII 
binding. All concentrations of inhibitor were conducted in triplicate. 
4.3:  Results 
4.3.1:  Receptor Specificity of RII-175 
 To test receptor specificity, I examined the effects of established enzyme 
treatments on RII-175 binding in the FACS assay described in chapter 3.  RII-175-his 
was incubated with RBCs that had been treated with chymotrypsin, trypsin, or an 
antibody against GpA [fig 20].  RII-175 was able to bind the untreated and chymotrypsin 
treated cells but only minimally bound the trypsin and GpA antibody treated cells. The 
fluorescence seen in the sample of trypsin treated RBCs with RII-175 is equivalent to that 
of RBCs not incubated with RII-175.  The reduction in binding seen in the GpA antibody 
sample is significant.  The binding pattern for trypsin and chymotrypsin is consistent with 
previously published data.   
4.3.2:  IC50 Curves 
 To look at the influence of the various parts of the receptor, I examined the IC50 
of 3’-siallylactose (SL), an unglycosylated peptide of GpA amino acids 27-59 that 
correspond to exon 3 (Pep), and 3’-siallylactose and the unglycosylated peptide (SLP).  
SL was tested for inhibition because it has been shown that SL on receptors is important 
for binding in rosetting assays and can inhibit binding slightly on its own.  The 
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unglycosylated peptide was tested for inhibition to determine the importance of the 
peptide backbone for binding of receptor by RII-175.  RII-175-his was incubated 
overnight at 4oC in the presence of varying concentrations of SL, Pep, or SLP in the 
absence of RBCs.  The samples were then incubated with RBCs and afterward incubated 
with anti-his antibody.  The compounds SL, Pep, or SLP inhibited binding in the FACS 
assay to varying degrees [fig 21].  The SL alone was able to inhibit RII-175 binding at an 
IC50 concentration of 13mM.  The Pep alone was unable to inhibit the RII-175 binding 
as shown by the IC50 concentration of >100mM.  The SLP was slightly worse inhibitor 
of RII-175 binding with an IC50 concentration of 40mM.   
4.4:  Discussion 
 The RII-175 expressed and purified is functional and binds to GpA.  The receptor 
specificity is supported by the RII-175 binding to chymotrypsin treated RBCs but not to 
trypsin treated cells.  The receptor specificity is further supported by the reduction in 
binding upon RBC treatment with anti-GpA antibody, which blocks RII-175 binding by 
specifically targeting the receptor.  It is also interesting that the trypsin cleaves at amino 
acids 31 and 39, which are in exon 3.  This implies that this region may be important for 
RII-175 binding.  The IC50 for SL was in the low milimolar range and implies that SL, 
while important for binding, is not the only portion of the receptor responsible for 
interaction with RII-175.  The peptide incontrast did not inhibit binding under similar 
conditions.  This may be due to the peptide lacking glycosylation, which is known to be 
important for binding.  Further studies would be to identify the minimal binding domain 
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of GpA by FACS inhibition assays using GpA truncations and GpA glycosylation 
mutants. 
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Figure 20: Erythrocyte binding by RII-175 in FACS. Trypsin 
treatment of erythrocytes or addition of an anti-glycophorin A 
antibody prevent binding of recombinant RII-175 while 
chymotrypsin treatment has no effect. 
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a)  
b)
 
c)  
 
Figure 21:  IC50 curves a) 3’-siallylactose (SL), b) peptide corresponding to truncation 
4A (peptide), c) SL + peptide 
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Chapter 5:  Protein/Protein Interaction Studies and Dimerization 
5.1:  Introduction 
 There are many methods that can be used to characterize protein/protein 
interactions.  These methods include pulldowns, analytical ultracentrifugation (AUC), 
and multi-angle-light-scattering (MALS).  All three methods will be discussed in this 
chapter.  In a pulldown, protein/protein interactions are characterized using a tagged 
protein of interest as “bait” for other proteins.  The tagged protein can be immobilized on 
agarose beads that are coupled to either a binding partner or antibody for the tag.  This 
allows for controlled experiments with a known amount of the tagged protein of interest.  
The immobilized protein can then be used to pull other proteins that can bind the “bait” 
out of solution.  The tagged protein of interest and its binding partners can then be 
determined through electrophoresis. The advantage of this method is that it can help to 
determine previously unknown binding partners for the “bait” protein and verify known 
binding partners.   The drawback of this method is that it cannot characterize the kinetics 
or stoichiometry of binding. 
 AUC has several advantages over pulldowns, one of which is that it can analyze 
molecular weights of complexes in solution along with affinity constants for complexes.  
In AUC, the samples can range from hundreds of Daltons to many millions of Daltons 
and can be used to obtain the average molecular weight of components in solution [20, 
21].  In a sedimentation equilibrium AUC experiment, samples are centrifuged at a set 
speed and the sample allowed to reach equilibrium where the amount of diffusion is equal 
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to that of the sedimentation.  At equilibrium, larger molecules will sediment towards the 
bottom of the sample channel and smaller molecules will remain towards the top of the 
channel.  Multiple speeds and concentrations can be analyzed together because the 
molecular weight at any point for a system at equilibrium is dependent on total 
concentration but is independent of rotor speed or radial position of the sample in the 
rotor [20, 21].   
The molecular weight of the sample can be analyzed using linear regression with 
set models of association [20, 21].  The first model used is usually a 1-component ideal 
model, which can give the average molecular weight of the molecules in solution.  It is 
best used with a known molecular weight of the possible species in solution.  If the 
average molecular weight is not that of the monomer and the monomer weight cannot be 
fit, it indicates that a monomer-n-mer equilibrium may be occurring.  If that is the case, a 
monomer-n-mer model can then be used to obtain the equilibrium constants for the 
molecule.  The n-mer can be varied to achieve the best fit and may be suggested by the 
average molecular weight from the 1-component ideal model [20, 21].  It is the advantage 
of being able to determine molecular weight of molecules in solution and the association 
constants for complexes that make this method ideal for the analysis of RII-175 
dimerization and interactions between RII-175 and components of its receptor GpA. 
MALS can also determine the molecular weight of proteins and protein 
complexes in solution [22, 23].  A typical MALS consists of a size-exclusion 
chromatography column coupled with two to three detectors.  The detectors commonly 
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used are a light-scattering detector and a refractive index detector.  An UV absorbance 
detector can also be used in conjunction with the other detectors.  The data from the 
detectors can be used to determine the size of the protein or complex as it is eluted from 
the size-exclusion column.  The molecular weight can be determined when both the light 
scattering and refractive index are determined because the amount a protein scatters light 
is directly proportional to its size.  While it is relatively straight forward to determine the 
molecular weight of a single protein, calculating the stoichiometry of a complex is 
slightly more complex.  To determine a stoichiometry for a complex from MALS data, 
one must assume a given stoichiometry and verify if that stiochiometry fits the data given 
[22, 23].  There are a few drawbacks to using MALS to characterize protein-protein 
interactions and they include that it requires a higher affinity interaction and equilibrium 
constants cannot be determined.      
In this chapter, I will describe experiments designed to characterize the 
dimerization of RII-175.  These experiments include a pulldown with tagged and 
untagged RII-175, AUC sedimentation equilibrium experiment with and without GpA, 
and MALS. 
5.2:  Materials and Methods 
5.2.1:  RII-175 self association as shown through Pulldowns. 1uL of 1:10 diluted 
untagged RII-175 and 1:10 diluted his tagged RII-175 were incubated together on Nickel-
agarose beads with His-tag buffer A for 30 min on ice.  The beads were then washed 3 
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times.  The beads were then resuspended in 10uL of SDS-PAGE dye and the samples run 
on a 8% SDS-PAGE gel. 
5.2.2:  AUC. 
5.2.2.1:  Optimization of Solution Conditions for RII-175 self association:  RII-175 
was buffer exchanged three times using a spin concentrator with either HEPES pH 7.4 
50mM NaCl, HEPES pH 7.4 100mM NaCl, or HEPES pH 7.4 150mM NaCl.  The buffer 
exchanged RII-175 was then diluted to an absorbance at 280nm of 0.8, 0.6, or 0.4. The 
samples were then run as an equilibrium experiment on a Beckman-Coulter ProteomeLab 
XL-A analytical ultra-centrifuge.  Ultrascan was used to analyze the data produced by the 
sedimentation experiments. 
5.2.2.2.:  Determination of the Influence of 3’-siallylactose and GpA Peptide 
Backbone on RII-175 Self Association. RII-175 was buffer exchanged three times using 
a spin concentrator with either HEPES pH 7.4 150mM NaCl 4.6uM sl, HEPES pH 7.4 
150mM NaCl 3uM sl, HEPES pH 7.4 150mM NaCl 1.5uM sl, HEPES pH 7.4 150mM 
NaCl 4.6uM pep, HEPES pH 7.4 150mM NaCl 3uM pep, HEPES pH 7.4 150mM NaCl 
1.5uM pep, HEPES pH 7.4 150mM NaCl 4.6uM slp, HEPES pH 7.4 150mM NaCl 3uM 
slp, or HEPES pH 7.4 150mM NaCl 1.5uM slp.  The buffer exchanged RII-175 was then 
diluted to an absorbance at 280nm of 0.6, 0.4, or 0.2 (4.6 uM, 3uM, or 1.5uM) according 
to the concentration of sl, pep, or slp in the buffer.  The samples were then run as an 
equilibrium experiment on a Beckman-Coulter ProteomeLab XL-A analytical ultra-
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centrifuge.  Ultrascan was used to analyze the data produced by the sedimentation 
experiments. 
5.2.3:  Characterization of RII-175 self association in solution using Multi-angle 
Light Scattering.  RII-175 at a concentration of either 9uM or 30uM in 300uL was 
buffer exchanged three times using a spin concentrator into MALS running buffer 
(HEPES pH 7.4 150mM NaCl) and concentrated to 300uL.  All 300uL of RII-175 
solution was filtered and then injected.  The MALS located in the Fremont lab is 
composed of an Waters 600S HPLC connected to a Wyatt WTC-030S5 gel filtration 
column (5um coated silica, 300-Å pore), a Waters 996 UV/VIS detector, a Wyatt 
Optilab-tex refractive index detector, and a Wyatt Dawn-heleos light scattering detector.  
Astra software is used in conjunction with the MALS to determine the experimental 
molecular weight of the resultant peaks. 
5.3:  Results 
5.3.1:  Optimization of RII-175 Pulldown to Characterize Self Association 
 RII-175 is a dimer in the crystal structure and the dimer model is supported by 
mutation studies, but direct interaction between RII-175 monomers has not been 
characterized. Therefore, a pulldown protocol was developed for RII-175 dimerization to 
show that RII-175 can interact with itself.  RII-175-his was used to pulldown RII-175 on 
nickel-agarose beads.  5uM RII-175-his and 5uM RII-175 were used in the pulldown.  In 
the pulldown, RII-175-his was able to bind RII-175 [fig 22].  The control of RII-175 on 
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the nickel-agarose beads had a very small amount of non-specific binding, but the amount 
seen is not enough to account for that seen in the RII-175/RII-175-his sample.   
5.3.2:  Optimization of Solution Conditions for RII-175 self association 
 The optimum conditions for the formation of the dimer in solution have not yet 
been defined and to determine the conditions a sedimentation equilibrium experiment 
was conducted with RII-175 in HEPES pH 7.4 buffer with either 50mM NaCl, 100mM 
NaCl, or 150mM NaCl at speeds of 7.5k, 9k, and 14k. The speeds were chosen according 
to the Laue equations were the lowest speed is greater than 1.4 for the equation (M/L)2 
and the highest speed is greater than 3 for the equation (H/L)2.  M is the ideal speed for 
the molecular weight as chosen from a RPM vs. molecular weight vs. approximate 
sedimentation coefficient chart originally developed by Chervenka in 1970.  Using the 
chart and a molecular weight of 70kDa for the monomer of RII-175, the speed for M was 
determined to be 9k.  L and H, the high and low speeds, were derived from the previous 
equations with the chosen M and were determined to be 7.5k and 14k respectively. 
Unfortunately, the 14k speed was at meniscus depletion for the dimer and no fit was 
obtained for any of the samples at this speed. Fits could also not be obtained for the 
highest concentration of RII-175 as based on the variance and residuals and may be due 
to overloading the cell. 
The samples at 4uM and 2uM RII-175 were first analyzed with a 1-component 
ideal model.   In the 1-component ideal model, molecular weight can be fixed, as well as, 
floated to obtain the average molecular weight of the sample and a fit for each weight 
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tested [table 2, fig 23-31].  The monomer and dimer weights, 70kDa and 140kDa 
respectively, were fixed for each sample and the fit obtained for each molecular weight.  
Neither weight was able to give a reasonable fit as seen by the high variance and the 
curved residuals.  Each sample was then tested with the molecular weight allowed to 
float.  When this was done, the variance and residuals became much more reasonable and 
the average molecular weight for each sample was obtained.  The average molecular 
weight for the 50mM NaCl, 100mM NaCl, and 150mM NaCl samples were 98.92kDa, 
101.6kDa, and 104.02kDa respectively.  The average molecular weight being between 
the ideal for the monomer and dimer molecular weight suggests a monomer/dimer 
equilibrium. 
Based on the results from the 1-component ideal model, a monomer/dimer 
equilibrium model was then used to analyze all samples at single concentrations at 7k, 9k, 
7k and 9k and at all concentrations at 7k and 9k [table 3 and fig 32-43].  The fits and Kds 
were obtained for each concentration of salt [table 3].  The Kd for the 50mM, 100mM, 
and 150mM NaCl sample was 13.19uM, 9.75uM, and 7.90uM respectively.  The result 
that the Kd is in the low micromolar range suggests that the RII-175 is a weak dimer in 
solution and that the salt concentration in solution has no influence on dimer formation.  
Based on these results, the salt concentration used in subsequent experiments was 
150mM NaCl.   
5.3.3:  Determination of the Influence of 3’-siallylactose and GpA Peptide Backbone 
on RII-175 Self Association 
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   A sedimentation equilibrium experiment was conducted with RII-175 in HEPES 
pH 7.4 150mM NaCl buffer with either SL, Pep, or SLP at a ratio to RII-175 of 1:1.  The 
samples were analyzed with a monomer/dimer equilibrium model and this model was 
chosen based on the results from the salt gradient experiment [table 4, fig 44-52].  The 
highest concentration of RII-175 was excluded from the analysis of the SL and SLP 
samples due to overloading and a small dynamic range of 0.6 to 0.8.  The lowest 
concentration of RII-175 was excluded from the analysis for the SL and SLP samples 
based on the small dynamic range due to underloading.  The Kd for the SL and SLP 
samples at 7.5k and 9k for the 3uM concentration was 4.19uM and 1.8uM respectively.  
The Kd for the Pep sample at all speed and concentrations was 2.20uM.  The resulting Kd 
for the SL, Pep, and SLP samples is similar but slightly lower to that obtained in the salt 
gradient, and this suggests that the presence of 3’-siallylactose and peptide alone and 3’-
siallylactose and peptide were unable to greatly influence the Kd of dimerization.  The 
small change in Kd may be due to the SL, PEP, and SLP interacting with the RII-175.   
5.3.4:  Determination of Oligomerization State in Solution by MALS 
 To determine if RII-175 is a dimer in solution, MALS was conducted on RII-175 
at two concentrations:  9uM and 30uM [fig 53].  9uM and 30uM are within the range of 
the Kd seen in AUC in identical buffer.  RII-175 ran at a molecular weight of 73 and 70 
kDa respectively.  This result is different from that seen in AUC experiments and may be 
due to dissociation of the complex on the column as the protein becomes diluted.   
5.4:  Discussion 
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 RII-175 is a weak dimer.  This is supported by the ability of RII-175-his to bind 
RII-175 in the pulldown.  This is also supported by the AUC data.  In the 1-component 
ideal model, the average molecular weight is around 100kDa, which is between that of 
the monomer and dimer, 70kDa and 140kDa respectively.  The monomer/dimer 
equilibrium model also supports the weak dimer with the Kd ranging from 7-13uM for the 
salt gradient sedimentation experiment and 1-14uM for the SL, Pep, and SLP 
experiments.  The dimer is also supported by previous mutation studies.  The MALS in 
contrast did not show any dimer in solution.  The protein may have dissociated on the 
column resulting in only a monomer peak.  This result may also be explained by the weak 
Kd as determined by the AUC.   
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Figure 22:  RII-175 dimer pull-down on Nickel-agarose beads 
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Salt concentration MW (kDa) variance (10^-6) 
50mM 4uM, 2uM 98.92 12.2 
50mM 4uM, 2uM 70 49 
50mM 4uM, 2uM 140 63.4 
100mM 4uM, 2uM 101.6 12.2 
100mM 4uM, 2uM 70 48.3 
100mM 4uM, 2uM 140 66.1 
150mM 4uM, 2uM 104.02 19.6 
150mM 4uM, 2uM 70 94.5 
150mM 4uM, 2uM 140 101 
 
Table 2:  1-Component Ideal Model fits for RII-175 in HEPES pH 7.4 with 50mM, 
100mM, or 150mM NaCl 
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Figure 23:  1-component ideal model using 70kDa molecular weight (left) 7.5k residuals 
(right) 9k residuals 
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Figure 24: 1-component ideal model using 140kDa molecular weight (left) 7.5k 
residuals (right) 9k residuals 
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Figure 25:  1-component ideal model using 98.9kDa molecular weight (left) 7.5k 
residuals (right) 9k residuals 
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Figure 26:  1-component ideal model using 70kDa molecular weight (left) 7.5k residuals 
(right) 9k residuals 
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Figure 27:  1-component ideal model using 140kDa molecular weight (left) 7.5k residuals 
(right) 9k residuals 
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Figure 28:  1-component ideal model using 101kDa molecular weight (left) 7.5k residuals 
(right) 9k residuals 
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Figure 29:  1-component ideal model using 70kDa molecular weight (left) 7.5k residuals 
(right) 9k residuals 
 
 
72 
 
 
150mM 
NaCl 
 
 
4uM 
 
 
2uM 
  
Figure 30:  1-component ideal model using 140kDa molecular weight (left) 7.5k residuals 
(right) 9k residuals 
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Figure 31:  1-component ideal model ussing 104kDa molecular weight (left) 7.5k 
residuals (right) 9k residuals 
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50mM       
concentration speed Kd (uM) variance (10^-6) 
4uM 7.5K 5.59 11.50 
4uM 9k 13.16 18.10 
4uM 7.5k/9k 11.58 15.00 
2uM 7.5K 12.46 5.79 
2uM 9k 21.13 8.70 
2uM 7.5k/9k 15.83 7.30 
4uM/2uM 7.5k/9k 13.19 11.50 
 
100mM       
concentration speed Kd (uM) variance (10^-6) 
4uM 7.5K 6.57 10.70 
4uM 9k 10.02 16.10 
4uM 7.5k/9k 8.44 13.60 
2uM 7.5K 7.68 7.80 
2uM 9k 11.92 10.80 
2uM 7.5k/9k 9.94 9.50 
4uM/2uM 7.5k/9k 9.75 11.40 
 
 
150mM       
concentration speed Kd (uM) variance (10^-6) 
4uM 7.5K 3.89 25.30 
4uM 9k 7.61 23.90 
4uM 7.5k/9k 7.09 27.20 
2uM 7.5K 8.59 9.36 
2uM 9k 8.56 12.80 
2uM 7.5k/9k 7.21 12.10 
4uM/2uM 7.5k/9k 7.90 18.60 
 
 
Table 3:  Kd and variance for monomer/dimer equilibrium model for 50mM, 100mM, 150mM 
NaCl samples 
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Figure 32:  monomer/dimer model overlays and residuals for 50mM NaCl, 4uM RII-175 
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Figure 33: monomer/dimer model overlays and residuals for 50mM NaCl, 2uM RII-175 
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Figure 34:  monomer/dimer model overlays and residuals for 50mM NaCl, 7k combined 
with 9k 
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Figure 35:  monomer/dimer model (left) 7.5k residuals, (right) 9k residuals for 50mM with 
4uM and 2 uM RII-175 
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100mM 
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figure 36:  monomer/dimer model overlays and residuals for 100mM NaCl, 4uM RII-
175 
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Figure 37:  monomer/dimer model overlays and residuals for 100mM NaCl, 2uM RII-
175 
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Figure 38:  monomer/dimer model overlays and residuals for 100mM NaCl, 7k combined 
with 9k 
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figure 39:  monomer/dimer model (left) 7.5k residuals, (right) 9k residuals for 100mM 
NaCl with 4uM and 2uM RII-175 
 
 
83 
 
 
150mM 
NaCl 
4uM/7k 4uM/9k 
 
  
 
 
 
figure 40:  monomer/dimer model overlays and residuals for 150mM NaCl, 4uM RII-175 
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figure 41:  monomer/dimer model overlays and residuals for 150mM NaCl, 2uM RII-
175 
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Figure 42:  monomer/dimer model overlays and residuals for 150mM NaCl, 7k 
combined with 9k 
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Figure 43:  monomer/dimer model (left) 7.5k residuals, (right) 9k residuals for 150mM 
NaCl and 4uM and 2uM RII-175 
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SL       
concentration speed Kd (uM) variance (10^-6) 
3uM 7.5K 9.52 3.36 
3uM 9k 15.82 4.61 
3uM 7.5k/9k 4.19 4.24 
   
 
Pep       
concentration speed Kd (uM) variance (10^-6) 
4.6uM 7.5K 10.80 8.61 
4.6uM 9k 12.50 14.60 
4.6uM 7.5k/9k 2.55 12.00 
3uM 7.5K 1.54 8.87 
3uM 9k 5.41 8.33 
3uM 7.5k/9k 0.89 8.30 
1.5uM 7.5K 0.89 7.11 
1.5uM 9k 1.44 8.11 
1.5uM 7.5k/9k 0.79 7.69 
4.6uM/3uM/1.5uM 7.5k/9k 1.55 9.50 
 
SLP       
concentration speed Kd (uM) variance (10^-6) 
3uM 7.5K 3.39 3.80 
3uM 9k 8.69 3.80 
3uM 7.5k/9k 1.80 4.59 
 
Table 4:  monomer/dimer model Kd and variance  for SL, pep, and SLP 
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SL 3uM/7k 3uM/9k 
 
 
 
 
  
figure 44: monomer/dimer model overlays and residuals for SL, 3uM RII-175 
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SL 3uM/7k, 9k 
 
 
7k 
 
9k 
 
figure 45: monomer/dimer model overlays and residuals for SL, 7k combined 
with 9k 
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PEP 4.6uM/7k 4.6uM/9k 
 
 
 
 
 
 
figure 46: monomer/dimer model overlays and residuals for PEP, 4.6uM RII-175 
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PEP 3uM/7k 3uM/9k 
 
  
 
  
figure 47:  monomer/dimer model overlays and residuals for PEP, 3uM RII-175 
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PEP 1.5uM/7k 1.5uM/9k 
 
 
 
 
  
figure 48:  monomer/dimer model overlays and residuals for PEP, 1.5uM RII-175 
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PEP 4.6uM/7k, 9k 3uM/7k, 9k 1.5uM/7k, 9k 
 
 
  
7k 
 
 
 
9k 
   
figure 49: monomer/dimer model overlays and residuals for PEP, 7k combined with 9k 
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PEP 
 
 
4.6uM 
  
3uM 
  
1.5uM 
  
figure 50: monomer/dimer model (left) 7.5k residuals, (right) 9k residuals for PEP, all 
speeds and concentrations 
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SLP 3uM/7k 3uM/9k 
 
 
 
 
  
figure 51: monomer/dimer model overlays and residuals for SLP, 3uM RII-175 
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SLP 3uM/7k, 9k 
 
 
 
 
 
 
figure 52: monomer/dimer model overlays and residuals for SLP, 7k combined with 
9k 
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a)  
b)  
 Figure 53: MALS data a) 9uM RII-175    b) 30uM RII-175 
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 Chapter 6:  Monoclonal Antibody Generation  
6.1:  Introduction 
 Production of antibodies is an important part of the immune response to 
pathogens.  It has been previously shown antibodies against EBA-175 offer marginal 
protection against P. falciparum [12, 13].  To further understand how antibodies interact 
with RII-175 and how they affect receptor binding, mAbs are being generated against 
RII-175.   
To produce mAbs, mice are injected with antigen and given boosts of the antigen 
at prescribed times [fig 54] [24].  The polysera of the mice is then tested for reactivity 
against the antigen used.  The spleen cells of a positive mouse are then harvested and 
fused with a myeloma cells that have a mutation in HGPRT and are grown in media that 
contains hypoxanthine and thymidine and aminopterin [fig 54].  Aminopterin blocks 
denovo purine and pyrimidine synthesis.  The spleen cells are fused with the myeloma 
cells and grown in media lacking hypoxanthine.  The fused cells will be able to survive 
but unfused myeloma cells and B cells will not.  The B cells do not survive because they 
are primary cells and the myeloma cells that do not fuse will not survive because they do 
not have a functional HGRPT enzyme.  The fused cells get a functional HGPRT from the 
B cells and the ability to grow and divide from the myeloma cells.  These hybridoma 
cells will then produce antibodies.  The hybridoma cells will then be subcloned to 
produce mAbs.  The mAbs can then be analyzed to for function and epitope [24]. 
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In this chapter, I describe how mAbs were generated against recombinant RII-175 
purified as described in chapter 2.  In this chapter I also address the development of an 
ELISA protocol for the detection of antibodies reactive to RII-175.  
6.2:  Materials and Methods 
6.2.1:  Antibody Generation.  Three mice were immunized with RII-175 by Kathy 
Sheehan and the Hybridoma Center at Washington University.  The mice were given an 
additional boost of RII-175 before polysera was collected.  Polysera was tested by ELISA 
as described below and the most reactive mouse (588) chosen for sacrifice.  The spleen 
cells of the chosen mouse were fused with myeloma cells by the Hybridoma Center.  The 
hybridomas were expanded and tested for reactivity against RII-175 by ELISA.   The 
resulting top 20 highest positive OD450 hybridomas were subcloned by the Hybridoma 
Center.  The resulting subclones will be analyzed by ELISA and positive subclones will 
be further subcloned by the Hybridoma Center and tested by ELISA.  The positive 
hybridomas will then be tested for function by FACS and epitope determined.  A terminal 
bleed was also taken from the mouse at the time of sacrifice. 
6.2.2:  Direct ELISA.  RII-175, RII-175-his and DBP were each diluted in Carbonate 
buffer pH 9.6 to a concentration of 100ug/100uL.  100uL of diluted protein was added to 
each well of three ELISA 96 well plates such that rows A to D were coated with RII-175 
(RII-175-his was added to column 1 instead of untagged RII-175) and rows E to H were 
coated with DBP.  The plates were then left at 4oC overnight to couple the protein to the 
plate.  The plates were then washed three times with PBS 0.5% tween20. 100uL of 2% 
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BSA in PBS 0.5% tween20 was added to each well to block and incubated at room 
temperature for one hour.  The plates were then washed three times with PBS 0.5% 
tween20.  Polysera was then diluted in a serial dilution starting at 1:100 and going to 
1:1,000,000 in PBS 0.5% tween20.  The polysera was then added to columns 2 through 6 
and incubated at room temperature for one hour.  At the same time a mouse anti-6Xhis 
antibody from Invitrogen was diluted to 1:500 and added to column 1 and incubated at 
room temperature for one hour.  The plates were then washed three times with PBS 0.5% 
tween20.  100uL of goat anti-mouse IgG antibody conjugated to HRP diluted 1:5000 was 
then added to all wells in columns 1 to 6 and incubated for one hour at room temperature. 
The plates were then washed three times with PBS 0.5% tween20.  100uL of TMB 
substrate was added to all wells in columns 1 to 6 and immediately quenched with 100uL 
2M Sulfuric acid.  Pictures of each plate were then taken and then the plates were read at 
a wavelength of 450nm. 
6.2.3:  Inhibition of RII-175.  His tagged 15mg/mL was diluted 1:10 in DMEM with 
10% FCS.  Polysera from mouse 588 immunized with RII-175 and mouse 592 
immunized with DBP were added to 25uL of diluted RII-175 to reach the desired 
concentration in a total of 50uL and the mixture incubated at 4oC overnight.  The mixture 
was then added to RBCs prepared as described in RII binding in chapter 4 and the FACS 
assay conducted as described in chapter 4. All concentrations of polysera were conducted 
in triplicate.  
6.3:  Results 
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6.3.1:  Reactivity of Mouse Polysera 
 Three mice were immunized with RII-175 to produce antibodies against RII-175.  
To determine if the mice produced antibodies against RII-175, polysera was obtained 
from each mouse.  The polysera from the three mice (588, 589, 590) was diluted in a 
serial dilution (titer) and tested in triplicate for reactivity against RII-175 by ELISA [fig 
55].  Mouse 588 had positive titers up to 1:100,000.  Mice 589 and 590 had positive titers 
up to 1:10,000.  Mouse 588 was chosen to be sacrificed to produce hybridomas because it 
had the highest titer of antibodies reactive to RII-175. 
6.3.2:  Reactivity of Fusions 
To produce immortal cell lines that can produce antibodies against RII-175, 
mouse 588’s spleen cells were fused with myeloma cells to produce hybridomas 
(fusions).  The fusions were tested twice for reactivity against RII-175 using ELISAs.  
The fusions were tested at two time points because a false positive can be seen at the first 
time point due to B-cells that have not fused with the myeloma cells and continue to 
produce antibodies until they die.  The second time point will not have production of 
antibodies from unfused B-cells.  The ELISAs resulted in 138 wells that had a positive 
reading of >0.2 at 450nm [fig 56-59].  The fusions with the 20 highest readings were 
chosen to be subcloned.  The fusions with the next 20 highest readings were chosen to be 
expanded and individually frozen for future studies [fig 60].  The other fusions were 
pooled and frozen for future studies.   
6.3.3:  Reactivity of First Round of Subcloned Cell lines 
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To ensure that the cell lines are clonal, the top 20 highest OD450 for the fusions 
were subcloned using a serial dilution in 96 well plates were row A was seeded with 
100cells/well, row B was seeded with 10cells/well, and rows C to H were seeded with 
1cell/well.  The subclones were tested for reactivity against RII-175 using ELISAs as 
described above.  The three highest OD450s in each cell line for wells with a dilution of 1 
cell/well were determined and the highest of these three wells was chosen to further 
subclone, while the other wells were expanded and frozen [table 5].  If a cell line did not 
have any positive readings in rows C to H, the top three highest OD450s in row B or row 
A were chosen and the highest of these three wells was chosen to further subclone, while 
the other wells were expanded and frozen [table 5].  These cell lines will need to undergo 
an extra round of subcloning to insure the culture is clonal.  Three cell lines (2F2, 2F7, 
and 2D7) failed to produce positive subclones at any dilution on multiple plates.  The 
other cell lines all produced positive subclones.   
6.3.4:  Inhibition of RII-175 RBC binding by Mouse Polysera 
 It is currently unknown how the antibodies produced by the mouse will interact 
with RII-175.  In order to begin to understand this, the mouse polysera was tested for its 
ability to inhibit RII-175 binding to RBCs.  Mouse polysera was incubated overnight with 
RII-175.  The mixture was then incubated with RBCs.  FACS was then done on the RBC 
mixtures.  All dilutions of polysera were able to inhibit binding of RII-175 to RBCs [fig 
61].  The dilution 1:5 had the greatest inhibition of binding followed by the 1:10 dilution.  
The 1:50 dilution showed minimal inhibition of binding.  The inhibition suggests that at 
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least some of the antibodies in the polysera can inhibit binding of RBCs by RII-175.   
Any mouse RBCs that may be present in the polysera should not inhibit binding because 
the terminal sialic acids on the O-glycans on GpA are acetylated.  This modification has 
been shown to block binding by RII-175 to the mouse RBCs.  Although the mouse RBCs 
should not inhibit binding, the result could also be explained by the presence of proteases 
or other components found in the polysera.  The purified monoclonal antibodies will 
eventually provide better evidence for inhibition of RII-175 binding to RBCs.    
6.4:  Discussion 
 Mice have been immunized with RII-175 and the titers of the mice tested.  All 
three mice had positive titers to 1:10,000 and mouse 588 was chosen to be sacrificed for 
formation of hybridomas.  The hybridomas were created and 20 chosen to be subcloned 
based on ELISA results.  Of the subcloned cell lines, 3 failed to produce positive 
subclones in the first round while the other 17 produced positive subclones.  The 
subclones still need to undergo a second round of subcloning before the antibodies can be 
deemed monoclonal.  The polysera was also tested for inhibition of RII-175 binding to 
RBCs.  The polysera was able to inhibit binding, but further characterization remains.  
The antibodies produced by the hybridomas will also be characterized individually for 
binding of RII-175, neutralization of binding in FACS assys, and epitope. 
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a)  
b) 
 
 
figure 54: a) diagram of the production of mAbs, b) diagram of requirements for fusion 
media [24] 
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a)  
b)
 
mouse1_588_polysera 
his tag 1/100 1/1000 1/10000 1/100000 1/1000000 
1.667 1.456 1.782 1.524 0.531 0.087 
1.707 1.33 1.693 1.394 0.561 0.076 
1.465 1.4 1.7 1.476 0.629 0.108 
 
c)
 
mouse2_589_polysera 
his 1/100 1/1000 1/10000 1/100000 1/1000000 
0.75 0.928 0.893 0.545 0.122 0.008 
0.794 1.058 1.009 0.611 0.116 0.002 
0.851 0.966 1.031 0.594 0.1 0.018 
 
d)
 
mouse3_590_polysera 
his 1/100 1/1000 1/10000 1/100000 1/1000000 
0.779 0.806 0.87 0.596 0.142 0.021 
0.702 0.815 0.922 0.577 0.139 0.005 
0.654 0.78 0.887 0.571 0.145 0.019 
 
figure 55:  a) graph of titers for mouse 588, b) ELISA plate and readings for mouse 588, 
c) ELISA plate and readings for mouse 589, d) ELISA plate and readings for mouse 590 
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figure 56:  ELISA results for plate 1 of fusions 
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figure 57: ELISA results for plate 2 of fusions 
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figure 58:  ELISA results for plate 3 of fusions 
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figure 59:  ELISA results for plate 4 of fusions 
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figure 60:  OD450 readings for the highest 20 positive fusions chosen for subcloning, the 
label on the x-axis refers to the plate number, row value, and well number 
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cell line well 
OD 
450 
dilution 
(cells/well) Subclone Freeze cell line well OD 450 
dilution 
(cells/well) Subclone Freeze 
2B2 G10 0.381 1 X   4A4 D2 0.585 1 X   
2B2 D9 0.365 1   X 4A4 C7 0.579 1   X 
2B2 C2 0.35 1   X 4A4 C3 0.568 1   X 
2D7 B2 0.14 10 X   4E10 B7 1.114 10 X   
2D7 B3 0.114 10   X 4E10 C6 0.688 100   X 
2A11 E7 0.433 1 X   4E10 C7 0.686 100   X 
2A11 E1 0.424 1   X 1A11 D11 0.198 1 X   
2A11 E2 0.358 1   X 1A11 A9 0.216 100   X 
4B1 H7 1.044 1 X   1A11 A7 0.195 100   X 
4B1 H11 1.02 1   X 2E2 E3 0.128 1 X   
4B1 H9 0.909 1   X 2E2 B2 0.128 10   X 
2G10 C11 0.233 1 X   2E2 D2 0.323 10   X 
2G10 A12 0.304 100   X 2F8 H3 1.371 1 X   
2G10 A9 0.301 100   X 2F8 H2 1.212 1   X 
3B1 C12 0.896 1 X   2F8 H6 1.210 1   X 
3B1 G12 0.857 1   X 2F11 E3 0.248 1 X   
3B1 D8 0.821 1   X 2F11 F4 0.237 1   X 
3D8 C12 0.488 1 X   2F11 B7 0.191 10   X 
3D8 C6 0.409 1   X 2F6 G5 0.370 1 X   
3D8 H11 0.385 1   X 2F6 G10 0.281 1   X 
4C1 C12 0.474 1 X   2F6 G4 0.253 1   X 
4C1 C3 0.449 1   X 1C7 D9 0.651 1 X   
4C1 H11 0.443 1   X 1C7 H3 0.398 1   X 
4B1 C6 0.685 1 X   1C7 G10 0.380 1   X 
4B1 C12 0.613 1   X 
      4B1 H11 0.57 1   X 
      
 
          table 5:  ELISA Results for Subcloned Cell Lines 
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figure 61: Inhibition of RII-175 binding to RBCs by Mouse 588 polysera in FACS 
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Chapter 7: Summary of Results and Discussion of Future Directions 
Approximately 2 million individuals a year die from malaria each year and an 
additional 200 million develop clinical illness characterized by the invasion and lysis of 
RBCs by Plasmodium parasites in the erythrocyte life stage [1, 2].  Plasmodium 
falciparum is the deadliest of the species of parasite that infect humans, and a large 
variety of proteins and cellular processes have been identified as potential targets for 
vaccines and drugs including EBA-175 [1, 2, 5].   
EBA-175 is part of the EBL family and the sialic acid dependent pathway and is 
important for binding erythrocytes [1, 5].  The receptor for EBA-175 is GpA, a 
transmembrane glycoprotein on the surface of RBCs [6, 15, 16].  GpA contains 15 O-
linked glycans and 1 N-linked glycan and the terminal α2-3 linked sialic acid from O-
linked glycans is essential for EBA-175 binding [15, 16].    
The structure of RII of EBA-175 reveals a dimer where each monomer is 
composed of one F1 and one F2 domain [5].  In the dimer, the F1 of one monomer 
interacts with the F2 of the other monomer in a handshake configuration creating two 
highly basic channels through the center of the dimer.  Six glycan binding sites can also 
be found in the dimer with 4 sites inside the channels and the other 2 on the receptor 
facing surface.  Mutations in the dimer interface and glycan binding sites showed a loss 
of RBC binding in rosetting assays indicating possible mechanisms of receptor/ligand 
interactions [5].   
7.1:  Components of the Receptor/Ligand System 
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The components of the receptor/ligand system consist of the RBC receptor GpA 
and the malaria ligand EBA-175.  Previously both EBA-175 and GpA had been produced 
using Pichia pastoris and CHO cells respectively [5, 14].  The previous protocol 
developed for the production of EBA-175 was labor and time intensive and required the 
use of glycosylation mutants [5].  Also, the protocol for production of GpA only 
produced transmembrane anchored GpA in small quantities [14].  These protocols were 
not easily adaptable for producing the large quantities needed for biophysical 
experiments.  As a result, a protocol to purify RII-175 and F2-175 from E. coli was 
developed and optimized for ease of production of large quantities of protein. The final 
yield for this protocol is approximately 1 to 5 mg/L refolding buffer.  A protocol for the 
production of full length GpA and GpA truncations using HEK293 cells was also 
developed and optimized.  The final yield for this protocol is approximately 13mg/L 
harvested media.  The production of purified RII-175 and GpA allows for further 
investigation into the interactions between RII-175 with itself and its receptor.   
7.2:  Characterization of RII-175/GpA Interactions 
To show that RII-175 and GpA (full length and truncations) are functional, a 
pulldown protocol was developed.  In the pulldown, RII-175 binds both full length Gpa 
and truncation 4; and it is likely that this region of GpA, amino acids 30 to 50, is the 
minimal binding site for RII-175.  RII-175 also binds truncation 2, which contains seven 
glycosylations and an additional three residues that could potentially be glycosylated, 
weakly and may be due to the large number of glycosylations.  The importance of the 
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glycosylations on GpA is also seen in the pulldown with the anion exchange purified 
GpA.  In this pulldown, RII-175 binds only the high molecular weight peaks which may 
correspond to a higher level of glycosylation. 
A second functional assay was developed to test the influence of inhibitors on 
RII-175 binding RBCs and to characterize its interactions with GpA.  In the FACS assay, 
RII-175 binds GpA on human RBCs and is detected through a fluorescently conjugated 
antibody against the 6X-his tag on the RII-175.  FITC-RII-175 was also developed to 
decreases the amount of time required for the FACS assay and can be used to test 
inhibitors but not antibodies against RII-175 because the label could interfere with the 
ability of antibodies to bind their epitope.  This assay was used to characterize the 
receptor specificity of the recombinant RII-175 and the inhibition of RII-175 binding by 
portions of the receptor. 
The RII-175 bound GpA on the RBCs and this is supported by the RII-175 
binding to chymotrypsin treated RBCs but not to trypsin treated cells.  The receptor 
specificity is further supported by the reduction in binding upon RBC treatment with anti-
GpA antibody, which blocks RII-175 binding by specifically targeting the receptor.  The 
receptor is composed of both an amino-acid backbone and a large number of 
glycosylations that terminate in an α2-3 linked sialic acid.  The ability of 3’-siallylactose 
and peptide backbone were tested for their ability to inhibit RII-175 binding.   The IC50 
for SL was in the low milimolar range and implies that SL, while important for binding, 
is not the only portion of the receptor responsible for interaction with RII-175.  Peptide 
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backbone and peptide backbone with SL was not able to inhibit better than SL alone.  
Further studies would be to verify the minimal binding domain of GpA by FACS 
inhibition assays using GpA truncations and GpA glycosylation mutants. 
7.3:  Dimerization of RII-175 
RII-175 is a weak dimer.  Previously, mutation studies were used to support the 
dimer model[5].  This is now also supported by data from pulldowns and AUC 
experiments but not by MALS.  RII-175-his is able to bind RII-175 in the pulldown 
indicating that the recombinant protein can interact with itself likely as a dimer.  
Dimerization is also supported by the AUC data.  In the 1-component ideal model, the 
average molecular weight is around 100kDa, which is between that of the monomer and 
dimer, 70kDa and 140kDa respectively.  The monomer/dimer equilibrium model also 
supports the dimer with the Kd ranging from 7-13uM for the salt gradient sedimentation 
experiment and 1-14uM for the SL, Pep, and SLP experiments.  This experiment has yet 
to be done in the presence of GpA.  In the presence of GpA, the RII-175 should transition 
to being mostly dimeric in the sample based on the proposed dimer model of binding.  
The MALS in contrast did not show any dimer in solution.  This result may also be 
explained by the weak Kd and on-column dissociation.   
7.4:  Production of mAb against RII-175  
Previous studies have shown that antibodies against RII-175 are present in patient 
sera[12, 13].  To better understand how antibodies against RII-175 interact with RII-175, 
monoclonal antibodies against RII-175 are being produced.  To date, three mice have 
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been immunized with RII-175 and the titers of the mice tested.  All three mice had 
positive titers to 1:10,000 and mouse 588 was chosen to be sacrificed for formation of 
hybridomas.  The hybridomas were created and 20 chosen to be subcloned based on 
ELISA results.  Of the subcloned cell lines, 3 failed to produce positive subclones in the 
first round while the other 17 produced positive subclones.  The subclones still need to 
undergo a second round of subcloning before the antibodies can be deemed monoclonal. 
While the polysera inhibited RII-175 binding to RBCs, the antibodies produced by the 
hybridomas have yet to be characterized individually for binding of RII-175, 
neutralization of binding in FACS assys, and epitope. 
7.5:  Future Directions 
 While dimerization has been shown to occur with RII-175 samples in the absence 
of receptor, the significance of dimerization in receptor binding has yet to be determined.  
This could be determined through sedimentation equilibrium experiments with RII-175 in 
the presence of receptor, co-crystallization of RII-175 with GpA, and the mechanism of 
inhibition of RII-175 binding by antibodies.   These experiments can also be used to 
verify the minimal binding domain of GpA.  Characterization of how RII-175 interacts 
with GpA can ultimately be used to develop vaccines against malaria.  
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